Skip to content

In Clinic Physical Activity in Persons With Multiple Sclerosis

Increasing Physical Activity in Recovered Persons With Multiple Sclerosis Through Daily Sensor Based Feedback and Weekly Focus Group Meetings: A Feasibility and Pilot II Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04186910
Acronym
PAMS
Enrollment
20
Registered
2019-12-05
Start date
2019-07-01
Completion date
2020-09-30
Last updated
2019-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Rehabilitation

Keywords

Multiple Sclerosis, Physical activity, Mobility, Self efficacy

Brief summary

The aim of htis study is to investigate the post intervention effects of daily feedback on actual physical activity levels derived from a wristworn accelerometer FITBIT combined with self-management training on in-clinic physical activity in persons with moderate to severe disability from MS.

Detailed description

Evidence from various sources indicate that physical activities and mobility practice are beneficial to maintain or increase functional levels in persons with Multiple sclerosis. Even so persons with moderate and severe disability from Multiple sclerosis are less active in daily life than their healthy counterparts. Also during hospital stay persons with MS tend to remain relatively sedentary outside of their rehabilitation sessions. Feedback about physical activity enabled by wearable sensors combined with behavioral strategies to improve self-efficacy and motivation are potential method increase physical activity in hospital inpatients. The primary purpose of this feasibility and interventional study was to determine whether a minimalist physical activity tracker-based feedback and self efficacy training would lead to an increase in physical activity, mobility and quality of life measures during recovery in a group of persons with MS compared to a control group that does not receive feedback. Secondary purpose was to verify if this intervention during recovery would lead to increased perceived physical activity in daily home life after discharge and over longer periods (Follow up at 6 weeks). The study participants will be 60 persons that have moderate to severe disability due to MS, that are admitted to MS Centre of the Santa Maria Nascente Institute, Don Gnocchi Foundation (Milan, Italy). Participants will all receive standard rehabilitation offered in the center. All participants will wear the accelerometer device (FitBit Charge tracker, FitBit Inc, CA, USA) 24 hours per day in order to measure physical activity levels during their hospital stay (3-4 weeks. The participants will be randomized to a group that has no feedback of physical activity level and a group that will have an active feedback intervention (AF). The active feedback intervention will consist of daily feedback, received through a Fitbit application downloaded on their telephones, on whether or not their target activity level was met and how far they were from the target. Additionally, the participants will participate in weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. Covariates such as age, sex, stage of change for physical activity behavior, clinical mobility, fatigue, health perception and goal commitment will be measured in all 60 participants both pre and post the intervention/hospital recovery period. The long-term effects on daily perceived functional mobility and self-efficacy will be investigated six weeks after discharge through questionnaires during a telephone call.

Interventions

BEHAVIORALControl group

The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.

BEHAVIORALFeedback group

The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.

Sponsors

Fondazione Don Carlo Gnocchi Onlus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Assessor will be blind to participants' intervention assignment

Intervention model description

Two arms interventional single blind pilot study

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of MS according to the McDonald's criteria McDonald Criteria 2010 * EDSS score \>4.5-7 * Freedom from relapses and steroid treatment for at least 1 month * Ability to walk at least 10 meters independently with or without support * MS without relapses in the last 3 months

Exclusion criteria

* Mini Mental State Examination (MMSE) score \< 20 * The presence of disabling pain or severe deficit of visual acuity * The presence of severe deficit in communication and severe dysmetry

Design outcomes

Primary

MeasureTime frameDescription
Number of passes with Fitbit wristbandChange from number of passes at baseline to number of passes after 4 weeks will be measured.A Fitbit wristband consists of an accelerometer and a memory unit and is used to collect mobility data, in the form of number of passes. More passes carried out during the period of wearing the wristband the better.
The 2 minute walking testChange on the measue will be measured. Will be applied at Day 1 and after 4 weeksThe 2 minute walking test is used to understand functional mobility. A smaller distance covered (in meters) represents a worse outcome.
The Self-Efficacy in Multiple Sclerosis ScaleChange on the measure will be measured. Will be applied at Day 1, after 4 weeks and after 10 weeksThe Self-Efficacy in Multiple Sclerosis Scale is a questionnaire of perceived self-efficacy of MS patients

Secondary

MeasureTime frameDescription
The Twelve Item MS Walking ScaleChange from Day 1 to 4 weeks and until 10 weeks will be measured. Will be applied at the Day 1, after 4 weeks and after 10 weeksThe Twelve Item MS Walking Scale is a questionnaire about the ability to walk (Minimum score=12, maximum score= 60; higher values represent a worse outcome).
The 10 meters walking scaleChange from Day 1 to day 28 will be measured. Will be applied at the Day 1 and after 4 weeksThe 10 meters walking test (10MWT) is a test in which the participant is timed while walking 10m at their comfortable speed. A lower gait velocity represents a worse outcome.
The Physical Activity Disability Survey-Revised questionnaireChange from Day 1 to 4 weeks and until 10 weeks will be measured. Will be applied at the Day 1, after 4 weeks and after 10 weeksThe Physical Activity Disability Survey-Revised is a questionnaire of physical activity
The Fatigue severity ScaleChange from Day 1 to 4 weeks and until 10 weeks will be measured. Will be applied at the Day 1, after 4 weeks and after 10 weeksThe Fatigue severity Scale is a questionnaire of perception of fatigue (Minimum score=9, maximum score= 63; higher values represent a worse outcome).
The Short Form-12 questionnaireChange from Day 1 to 4 weeks and until 10 weeks will be measured. Will be applied at baseline Day 1 after 4 weeks and after 10 weeksThe Short Form-12 questionnaire is comprised of two domains, physical and mental and gives two composite scores that reflect the perceived health of the participant (normative score value= 50).
The EQ-5D visual analogue scaleChange from Day 1 to 4 weeks and until 10 weeks will be measured. Will be applied at the Day 1, after 4 weeks and after 10 weeksThe EQ-5D visual analogue scale is a measure of health-related quality of life (Minimum score=5, maximum score= 25; higher values represent a worse outcome).

Countries

Italy

Contacts

Primary ContactMaria Chiara Carrozza, PhD
mcarrozza@dongnocchi.it+390210308
Backup ContactMarco Rovaris, MD
mrovaris@dongnocchi.it+390210308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026